Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.

Autor: Clot, Pierre-Francois1 (AUTHOR) Pierre-Francois.Clot@sanofi.com, Farenc, Christine2 (AUTHOR), Suratt, Benjamin T.3 (AUTHOR), Krahnke, Tillmann4 (AUTHOR), Tardat, Agnes5 (AUTHOR), Florian, Peter6,7 (AUTHOR), Pomponio, Robert8 (AUTHOR), Patel, Naimish9 (AUTHOR), Wiekowski, Maria10 (AUTHOR), Lin, Yong11 (AUTHOR), Terrier, Benjamin12 (AUTHOR), Staudinger, Heribert10 (AUTHOR)
Zdroj: Respiratory Research. 2/28/2024, Vol. 25 Issue 1, p1-11. 11p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje